Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.04
+1.5%
$1.05
$0.86
$3.60
$62.69M0.09293,421 shs73,621 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$7.43
+1.0%
$7.56
$4.32
$10.50
$172.20M1.63262,689 shs47,266 shs
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
$1.80
+10.1%
$1.46
$0.87
$9.25
$60.05M0.39761,907 shs254,836 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.47
+3.8%
$0.40
$0.29
$1.07
$106.58M1.272.42 million shs391,515 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.00%-1.92%-0.97%-19.05%-68.62%
INmune Bio, Inc. stock logo
INMB
INmune Bio
-3.79%-1.34%-6.84%-6.24%-27.49%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
+1.24%0.00%+10.14%+18.12%-79.46%
Vaxart, Inc. stock logo
VXRT
Vaxart
-2.36%-1.60%+0.63%-8.63%-45.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.281 of 5 stars
3.72.00.00.02.01.70.6
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.8519 of 5 stars
3.60.00.00.02.71.70.6
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
1.8511 of 5 stars
3.43.00.00.01.90.00.6
Vaxart, Inc. stock logo
VXRT
Vaxart
1.9307 of 5 stars
3.51.00.00.02.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3.33
Buy$7.33608.53% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
3.17
Buy$22.80206.86% Upside
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2.80
Moderate Buy$10.20468.25% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00542.40% Upside

Current Analyst Ratings Breakdown

Latest ABOS, INMB, VXRT, and OTLK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/28/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
3/28/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $11.00
3/27/2025
Vaxart, Inc. stock logo
VXRT
Vaxart
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.50 ➝ $2.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$4.61 per shareN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$50K3,415.42N/AN/A$2.07 per share3.59
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/A($1.57) per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$47.40M2.25N/AN/A$0.38 per share1.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%8/12/2025 (Estimated)
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%8/7/2025 (Estimated)
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$82.46M-$0.27N/AN/AN/A-431.61%-110.46%-62.78%8/14/2025 (Estimated)

Latest ABOS, INMB, VXRT, and OTLK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q2 2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/13/2025Q1 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.56-$0.48+$0.08-$0.48N/AN/A
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
3/27/2025Q4 2024
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.47-$0.62-$0.15-$0.62N/AN/A
3/27/2025Q4 2024
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.54-$0.40+$0.14-$0.40N/AN/A
3/20/2025Q4 2024
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.14
10.43
10.43
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.59
2.59
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/A
0.32
0.64
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.83
0.83

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
11.20%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
9.30%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.20%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
4.80%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2060.57 million55.81 millionOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1022.98 million14.37 millionOptionable
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2033.57 million30.48 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.22 million221.57 millionOptionable

Recent News About These Companies

Vaxart (NASDAQ:VXRT) Raised to Hold at Wall Street Zen
Vaxart Names Grasman as CFO, Succeeding Lee

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$1.03 +0.02 (+1.47%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$7.43 +0.07 (+0.95%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Outlook Therapeutics stock logo

Outlook Therapeutics NASDAQ:OTLK

$1.80 +0.17 (+10.12%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.47 +0.02 (+3.78%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.